📰 4 sources covering this story

Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%

First covered 1 hrs ago · latest take 18 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%
CNBC
CNBC18 mins ago
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 100%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Quartz
Quartz39 mins ago
Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed
Reuters
Reuters1 hrs ago
Merck, Moderna say melanoma vaccine meets goals in large trial
Merck, Moderna say melanoma vaccine meets goals in large trial  Reuters
STAT News
STAT News🏁 first to report1 hrs ago
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →